source
- Argenx to acquire Forte Biosciences for $2.2 billion, adding anti-CD122 antibody FB102Argenx announced it will buy Texas‑based Forte Biosciences in a transaction valued at roughly $2.2 billion. The offer of $77 per share represents an 86 % premium to Forte’s recent average price. T…
- Biotech confidence surges in 2026 as China leads growth and deal activity spikesIndustry observers noted a marked shift in tone at two major 2026 biotech gatherings – the DIA China meeting in Shanghai and the BIO International Convention in San Diego – where participants expre…